secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001104659-24-025196
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q4 net loss $49.1M; cash $526.4M; BT8009 Phase 2/3 trial recruiting
--------------------------------------------------------------------------------

- Net loss $49.1M ($1.16/share) in Q4 2023 vs $30.0M prior year; full year loss $180.7M ($5.08).
- Cash $526.4M as of Dec 31, 2023, up from $339.2M; financial runway expected into 2026.
- BT8009 Phase 2/3 Duravelo-2 registrational trial for metastatic urothelial cancer now active and recruiting.
- BT8009 showed 38% objective response rate in EV-naïve mUC patients; differentiated safety profile.
- Stephen Sands appointed to Board; former chairman of Lazard's Global Healthcare Group, serves on Audit and Strategic Committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465924025196/0001104659-24-025196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465924025196/tm246555d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-025196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer